Literature DB >> 29887323

Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection.

Marina R Pulido1, Meritxell García-Quintanilla1, Jerónimo Pachón2, Michael J McConnell3.   

Abstract

Outer membrane complex (OMC) vaccines, which contain antigens from the bacterial outer membrane, have been developed for multiple Gram-negative bacteria. However, OMC vaccines demonstrate high endotoxin activity due to the presence of lipopolysaccharide in the bacterial outer membrane, thus precluding their use in humans. We isolated OMCs from an LPS-deficient strain of A. baumannii (IB010) which completely lacks LPS due to a mutation in the lpxD gene. OMCs from IB010 demonstrated a more than 10,000-fold reduction in endotoxin activity compared to OMCs from wild type A. baumannii. Vaccination with IB010 OMCs produced similar levels of antigen-specific IgG and IgM after two administrations compared to wild type OMCs, and resulted in a similar reduction in post-infection spleen bacterial loads and serum pro-inflammatory cytokine levels. Vaccination with IB010 OMCs provided significant protection against infection compared to control mice, indicating the LPS-free OMCs could contribute to vaccine strategies for preventing infection by A. baumannii.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Lipopolysaccharide; Outer membrane complexes; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 29887323     DOI: 10.1016/j.vaccine.2018.05.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Innovative Immunization Strategies for Antivenom Development.

Authors:  Erick Bermúdez-Méndez; Albert Fuglsang-Madsen; Sofie Føns; Bruno Lomonte; José María Gutiérrez; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-11-02       Impact factor: 4.546

2.  Sequential Vaccination With Heterologous Acinetobacter baumannii Strains Induces Broadly Reactive Antibody Responses.

Authors:  Gathoni Kamuyu; Yat Suen Cheng; Sam Willcocks; Chidchamai Kewcharoenwong; Pattarachai Kiratisin; Peter W Taylor; Brendan W Wren; Ganjana Lertmemongkolchai; Richard A Stabler; Jeremy Brown
Journal:  Front Immunol       Date:  2021-07-30       Impact factor: 7.561

Review 3.  Vaccine development to control the rising scourge of antibiotic-resistant Acinetobacter baumannii: a systematic review.

Authors:  Ravinder Singh; Neena Capalash; Prince Sharma
Journal:  3 Biotech       Date:  2022-03-02       Impact factor: 2.406

Review 4.  Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.

Authors:  Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

5.  Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice.

Authors:  Xin Li; Chao Pan; Zhicheng Liu; Peng Sun; Xiaoting Hua; Erling Feng; Yunsong Yu; Jun Wu; Li Zhu; Hengliang Wang
Journal:  Microb Biotechnol       Date:  2021-03-23       Impact factor: 5.813

Review 6.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.